Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $10.00.

Several analysts have recently weighed in on MGX shares. Weiss Ratings raised Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Wall Street Zen downgraded Metagenomi from a “hold” rating to a “sell” rating in a report on Saturday, March 21st.

Metagenomi Stock Performance

Metagenomi stock opened at $1.41 on Friday. Metagenomi has a fifty-two week low of $1.25 and a fifty-two week high of $3.95. The company has a market capitalization of $53.09 million, a P/E ratio of -0.59 and a beta of 0.63. The stock has a 50-day simple moving average of $1.45 and a 200-day simple moving average of $1.69.

Metagenomi (NASDAQ:MGX) last posted its earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.02). Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. The firm had revenue of $3.91 million during the quarter, compared to analysts’ expectations of $7.33 million. As a group, analysts forecast that Metagenomi will post -2.06 earnings per share for the current year.

Institutional Trading of Metagenomi

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its holdings in shares of Metagenomi by 1,840.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock valued at $36,000 after purchasing an additional 14,389 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Metagenomi by 508.5% in the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after purchasing an additional 15,682 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Metagenomi in the 3rd quarter valued at about $64,000. Panagora Asset Management Inc. purchased a new stake in shares of Metagenomi in the 4th quarter valued at about $53,000. Finally, Quadrature Capital Ltd purchased a new stake in Metagenomi during the 4th quarter valued at approximately $55,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.